TROG Cancer Research
Members Login   CQMS Login

Lung trials now recruiting patients

Our lung cancer trials are focused on the benefits and side effects of radiotherapy.

TROG 16.03 (CORE) - this study aims to show that the addition of SBRT (stereotactic body radiotherapy) to standard of care improves progression free survival for patients with extra-cranial oligiometastatic disease that has spread from their lung, breast and/or prostate cancer

Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG


TROG 16.01 (NIVORAD) - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

Primary sponsor: The University of Sydney
Collaborating groups: ALTG and TROG


TROG 11.03 (P_LUNG) - this study investigates whether adding chemotherapy to a short course of radiotherapy results in a greater improvement in symptoms and overall wellbeing compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC).

Primary sponsor: TROG

 

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.